Drug Search Results
More Filters [+]

Erlotinib

Alternative Names: erlotinib, tarceva, osi-774, osi774, SGT210, SGT 210, SGT-210
Latest Update: 2024-06-11
Latest Update Note: Clinical Trial Update

Product Description

Erlotinib is used to treat certain types of non-small cell lung cancer that has spread to nearby tissues or to other parts of the body in patients who have already been treated with at least one other chemotherapy medication and have not gotten better. Erlotinib is also used in combination with another medication (gemcitabine [Gemzar]) to treat pancreatic cancer that has spread to nearby tissues or to other parts of the body and cannot be treated with surgery. Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a605008.html)

Mechanisms of Action: EGFR Inhibitor,TK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Erlotinib

Countries in Clinic: Australia, Austria, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Kazakhstan, Korea, Latvia, Mexico, Netherlands, Norway, Peru, Poland, Portugal, Romania, Saudi Arabia, Spain, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 17

Highest Development Phases

Phase 3: Non-Small-Cell Lung Cancer

Phase 2: Biliary Tract Cancer|Bladder Cancer|Breast Cancer|Clear Cell Sarcoma|Hepatocellular Carcinoma|Intestinal Cancer|Liver Cancer|Oncology Solid Tumor Unspecified|Oncology Unspecified|Renal Cell Carcinoma

Phase 1: Gastrointestinal Cancer|Kidney Cancer|Kidney Diseases|Mouth Cancer|Pregnancy Outcomes|Small Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BRISK

P2

Recruiting

Oncology Solid Tumor Unspecified

2025-01-31

IRX4204 NSCLC 1 01 2015

P1

Suspended

Non-Small-Cell Lung Cancer

2024-12-31

27%

IRX4204 NSCLC 1 01 2015

P1

Suspended

Non-Small-Cell Lung Cancer

2024-12-31

27%

EGFR

P2

Recruiting

Non-Small-Cell Lung Cancer

2024-12-31

57%

EGFR

P2

Recruiting

Non-Small-Cell Lung Cancer

2024-12-31

57%

EGFR

P2

Recruiting

Non-Small-Cell Lung Cancer

2024-12-31

57%

NRG-LU002

P2

Active, not recruiting

Non-Small-Cell Lung Cancer

2023-12-20

Recent News Events